Novavax Concludes Filing For WHO's Emergency Use Listing For COVID-19 Vaccine

Comments
Loading...
  • Novavax Inc NVAX has completed its rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of NVX-CoV2373, its COVID-19 vaccine candidate.
  • Today's filing by Novavax is in addition to a previous filing to WHO by Novavax and Serum Institute of India Pvt Ltd (SII).
  • The submission includes data from PREVENT-19 Phase 3 trial of 30,000 participants in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall. 
  • Related Link: Why Are Novavax Shares Trading Higher Today?
  • Novavax executed an advance purchase agreement with the European Commission to supply a minimum of 20 million doses and up to 100 million initial doses, with an option to purchase an additional 100 million doses through 2023.
  • The Company achieved a capacity of 100 million doses per month for its COVID-19 vaccine as of the end of Q3.
  • It is on track to achieve a capacity of 150 million doses per month by the end of Q4 and expect to have the capacity of over 2 billion annual doses in 2022
  • Novavax ended Q3 with $1.9 billion in cash, cash equivalents, and restricted cash.
  • Price Action: NVAX shares dropped 8.97% at $163.32 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!